RESUMO
Busulfan (Bu) is used as a myeloablative agent in conditioning regimens before allogeneic hematopoietic cell transplantation (allo-HCT). In line with strategies explored in adults, patient outcomes may be optimized by replacing cyclophosphamide (Cy) with or without melphalan (Mel) with fludarabine (Flu). We compared outcomes in 2 consecutive cohorts of HCT recipients with a nonmalignant HCT indication, a myeloid malignancy, or a lymphoid malignancy with a contraindication for total body irradiation (TBI). Between 2009 and 2012, 64 children received Flu + Bu at a target dose of 80-95 mg·h/L, and between 2005 and 2008, 50 children received Bu targeted to 74-80 mg·h/L + Cy. In the latter group, Mel was added for patients with myeloid malignancy (n = 12). Possible confounding effects of calendar time were studied in 69 patients receiving a myeloablative dose of TBI between 2005 and 2012. Estimated 2-year survival and event-free survival were 82% and 78%, respectively, in the FluBu arm and 78% and 72%, respectively, in the BuCy (Mel) arm (P = not significant). Compared with the BuCy (Mel) arm, less toxicity was noted in the FluBu arm, with lower rates of acute (noninfectious) lung injury (16% versus 36%; P = .007), veno-occlusive disease (3% versus 28%; P = .003), chronic graft-versus-host disease (9% versus 26%; P = .047), adenovirus infection (3% versus 32%; P = .001), and human herpesvirus 6 infection reactivation (21% versus 44%; P = .005). Furthermore, the median duration of neutropenia was shorter in the FluBu arm (11 days versus 22 days; P < .001), and the patients in this arm required fewer transfusions. Our data indicate that Flu (160 mg/m(2)) with targeted myeloablative Bu (90 mg·h/L) is less toxic than and equally effective as BuCy (Mel) in patients with similar indications for allo-HCT.
Assuntos
Bussulfano/uso terapêutico , Ciclofosfamida/uso terapêutico , Neoplasias Hematológicas/terapia , Transplante de Células-Tronco Hematopoéticas , Agonistas Mieloablativos/uso terapêutico , Condicionamento Pré-Transplante/métodos , Vidarabina/análogos & derivados , Infecções por Adenoviridae/mortalidade , Adolescente , Criança , Pré-Escolar , Feminino , Seguimentos , Doença Enxerto-Hospedeiro/mortalidade , Neoplasias Hematológicas/imunologia , Neoplasias Hematológicas/patologia , Humanos , Lactente , Recém-Nascido , Pulmão/imunologia , Pulmão/patologia , Masculino , Infecções por Roseolovirus/mortalidade , Análise de Sobrevida , Transplante Homólogo , Resultado do Tratamento , Vidarabina/uso terapêutico , Adulto JovemRESUMO
After minor surgery in a hospital, 7 patients suffered serious infectious complications. Microbiological analysis revealed an infection caused by contamination of the intravenous anaesthetic propofol. Several studies have shown that the administration of intravenous medication is a risky process that is prone to errors; these errors can result in harm to the patient. Within the Dutch project 'Safe medical care', the intravenous administration of medication has been chosen as one of the ten most important areas in which to patient safety can be improved. To enhance patient safety it is important to identify the separate steps that are the most prone to error, based on a good risk analysis. A systematic and coordinated approach is crucial for success in this process.